Efficacy and safety of cinobufacini capsules combined with oxaliplatin-based chemotherapy for advanced colorectal cancer: a human systematic review and meta-analysis.
[BACKGROUND] Patients with stage III-IV colorectal cancer (CRC) face poor prognosis due to metastases and limited treatment options.
- 95% CI 1.10-1.25
- RR 1.18
APA
Wang J, Gao Q, et al. (2026). Efficacy and safety of cinobufacini capsules combined with oxaliplatin-based chemotherapy for advanced colorectal cancer: a human systematic review and meta-analysis.. Frontiers in pharmacology, 17, 1709044. https://doi.org/10.3389/fphar.2026.1709044
MLA
Wang J, et al.. "Efficacy and safety of cinobufacini capsules combined with oxaliplatin-based chemotherapy for advanced colorectal cancer: a human systematic review and meta-analysis.." Frontiers in pharmacology, vol. 17, 2026, pp. 1709044.
PMID
41693778
Abstract
[BACKGROUND] Patients with stage III-IV colorectal cancer (CRC) face poor prognosis due to metastases and limited treatment options. In China, cinobufacini capsules are widely used as a complementary medicine, but evidence for their clinical value remains insufficient.
[METHODS] Systematic searches were conducted across seven databases, including Chinese National Knowledge Infrastructure (CNKI), WanFang Database, China Biological Medicine Database (CBM), PubMed, Embase, the Cochrane Library, and Web of Science, from their inception to 30 June 2025. The primary outcome was disease control rate (DCR), and the secondary outcomes were objective response rate (ORR), CD4 T cells, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA-125), and adverse reactions. This study strictly followed the PRISMA guidelines and used RevMan 5.3, Stata 15, and GRADEpro for data analysis.
[RESULTS] The analysis showed that the combination therapy resulted in a higher DCR (RR = 1.18, 95% CI: 1.10-1.25; < 0.0001) and ORR (RR = 1.40, 95% CI: 1.23-1.60; < 0.0001), reduced CEA levels (WMD = -7.84, 95% CI: -10.43 to -5.23; < 0.0001), CA-125 levels (WMD = -9.36, 95% CI: -12.80 to -5.92; < 0.0001), and CA19-9 levels (WMD = -11.38, 95% CI: -12.66 to -10.11; < 0.0001), as well as higher CD4 T-cell levels (WMD = 2.74, 95% CI: 1.99-3.49; < 0.0001). Additionally, the combination therapy could decrease the incidence of adverse reactions including leukocyte toxicity (RR = 0.59, 95% CI: 0.48-0.71; < 0.0001), gastrointestinal toxicity (RR = 0.79, 95% CI: 0.62-0.99; = 0.03), and myelosuppression (RR = 0.65, 95% CI: 0.46-0.92; = 0.01). The level of evidence was assessed as moderate for DCR and low for ORR.
[CONCLUSION] Cinobufacini combined with oxaliplatin-based chemotherapy may enhance short-term efficacy, immune function, and safety in advanced CRC. However, due to limitations of existing RCTs, these findings should be interpreted cautiously, and further large-scale, high-quality trials are required.
[METHODS] Systematic searches were conducted across seven databases, including Chinese National Knowledge Infrastructure (CNKI), WanFang Database, China Biological Medicine Database (CBM), PubMed, Embase, the Cochrane Library, and Web of Science, from their inception to 30 June 2025. The primary outcome was disease control rate (DCR), and the secondary outcomes were objective response rate (ORR), CD4 T cells, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA-125), and adverse reactions. This study strictly followed the PRISMA guidelines and used RevMan 5.3, Stata 15, and GRADEpro for data analysis.
[RESULTS] The analysis showed that the combination therapy resulted in a higher DCR (RR = 1.18, 95% CI: 1.10-1.25; < 0.0001) and ORR (RR = 1.40, 95% CI: 1.23-1.60; < 0.0001), reduced CEA levels (WMD = -7.84, 95% CI: -10.43 to -5.23; < 0.0001), CA-125 levels (WMD = -9.36, 95% CI: -12.80 to -5.92; < 0.0001), and CA19-9 levels (WMD = -11.38, 95% CI: -12.66 to -10.11; < 0.0001), as well as higher CD4 T-cell levels (WMD = 2.74, 95% CI: 1.99-3.49; < 0.0001). Additionally, the combination therapy could decrease the incidence of adverse reactions including leukocyte toxicity (RR = 0.59, 95% CI: 0.48-0.71; < 0.0001), gastrointestinal toxicity (RR = 0.79, 95% CI: 0.62-0.99; = 0.03), and myelosuppression (RR = 0.65, 95% CI: 0.46-0.92; = 0.01). The level of evidence was assessed as moderate for DCR and low for ORR.
[CONCLUSION] Cinobufacini combined with oxaliplatin-based chemotherapy may enhance short-term efficacy, immune function, and safety in advanced CRC. However, due to limitations of existing RCTs, these findings should be interpreted cautiously, and further large-scale, high-quality trials are required.
같은 제1저자의 인용 많은 논문 (5)
- "A diamond-shaped" penoplasty technique with or without concurrent suprapubic liposuction for adult-acquired buried penis: clinical outcomes and patient satisfaction rates.
- A Systematic Review of Patient-Reported Outcomes for Cosmetic Indications of Botulinum Toxin Treatment.
- Impact of diagnosis-related group systems on inpatient expenditures and medical quality for children with leukemia: evidence from real-world data.
- A preliminary study to evaluate efficacy and safety of Lugol's solution following radioiodine for remnant ablation in differentiated thyroid cancer.
- Lentinan inhibits breast cancer cell growth through the dual downregulation of tumor-promoting effectors CD133 and SCGB2A2.